Team:HZAU-China/Safety/Security Evaluatio
From 2013.igem.org
Line 28: | Line 28: | ||
h1, h2, h3, h4, h5, h6 { | h1, h2, h3, h4, h5, h6 { | ||
border-bottom: none; | border-bottom: none; | ||
- | |||
font-family:arial, sans-serif; | font-family:arial, sans-serif; | ||
} | } |
Revision as of 12:22, 27 September 2013
The reason why we take Rabies G protein as our title
Rabies is caused by the rabies virus infection in the central nervous system characterized by violations of fatal zoonotic diseases. Once infected by the disease, the mortality rate is almost 100%. Studies have shown that rabies virus can cross the human blood-brain barrier, then to invade the brain. But in the human body it can not be cleared mainly because of the ability to evade the host immune clearance. Escape mechanism is the key for the rabies virus inhibiting the inflammatory response, as well as inhibiting the body's resistance to innate immunity and acquired immunity, then clear up the viral infection caused by the T-lymphocytes. It is effective to use rabies virus vaccine vaccination to prevent and control the incidence of rabies. Currently, people widely employ the primary cell culture vaccines and refine passage cells to purify vaccine. Although these vaccines have better immune effect, people still cannot receive the high cost of production. To solve the problem, transportation and storage must rely on the low-temperature "cold chain". What is more, the mode of administration and other factors will limit the application to store rabies virus. It is inconvenient to inoculate the reservoir hosts, for example, dogs, foxes and other wild or domestic animal. Inoculating the source of rabies virus effectively may cut off the route of transmission, which still depends on developing a new generation of genetically engineered recombinant vaccines. The most successful experience in Europe and other developed countries for rabies control is the use of attenuated vaccine and recombinant live vector vaccine to immune the wildlife. In recent years, with the increasing number of dogs, cats and other pets, rabies is becoming more and more serious. In order to respond the policy of our government to increase the force of compulsory vaccination to animals, we need to develop a safe and effective rabies weak poison vaccine to finish the target. So we choose the Rabies G protein as our title, and we hope one day we can use the flea carried with our vaccine to end up the rabies virus disease.
I. The level of Laboratory Biosafety
The biological methods used in our laboratory are just the normal operation such as PCR, digestion, ligation, electric conversion and so on. Well protective measures have been taken to the use and storage of toxic reagents. Besides, we do not try any dangerous experiment operation. Therefore, according to《Laboratory Biosafety Manual》 - Third Edition(Edited by WTO), the level of security for the genetic manipulation is Class I .
II .The safety Evaluation of rabies G protein
1 The source of the G protein
We got it from the State Key Laboratory of Agricultural Microbiology.
2 Is there long-term security applications record?
Yes. Our school has the exact record of the poison to extend and the main biological characteristics of monitoring. Besides, we have the special staff to record and store them.
3 Did it cause any adverse impact on human health or the environment?
Rabies virus strains ERA glycoprotein (G) gene ... The glycoprotein can induce the body to produce neutralizing antibody. Besides, the structure of the rabies virus and the cell receptors are under the influence of the G protein. Currently, No related stories have proved that rabies G protein caused any adverse impact on human health or the environment.
So from the website https://2013.igem.org/Safety/Risk_Group_Table.,we determine the security level of rabies G protein type II.